Breaking News
October 23, 2018 - Despite lower risk factors, black men have higher rates of recidivism
October 23, 2018 - Study finds why pregnant women in mainland China, Hong Kong and Taiwan prefer cesarean delivery
October 23, 2018 - AbbVie’s U-ACHIEVE Phase 2b/3 dose-ranging study improves outcomes in patients with ulcerative colitis
October 23, 2018 - NCI grant awarded to Abramson Cancer Center to study CAR T cells In solid tumors
October 23, 2018 - Scientists use electron microscope to study chemical transformation in catalytic cross-coupling reaction
October 23, 2018 - Research offers new hope to men who received childhood cancer treatment
October 23, 2018 - Adverse Childhood Experiences Tied to Burnout in BSN Students
October 23, 2018 - High levels of oral disease among elite athletes affecting performance
October 23, 2018 - Study examines effect of immediate vs delayed pushing during labor on delivery outcomes
October 23, 2018 - LU-RRTC to spearhead capacity-building efforts for racial and ethnic populations
October 23, 2018 - Maintenance therapy with olaparib improves progression-free survival in advanced ovarian cancer patients
October 23, 2018 - Organic food may protect against cancers finds study
October 23, 2018 - Interweaving anxiety disorder associated with stuttering remains unrecognized
October 23, 2018 - Cannabis oil shown to significantly improve Crohn’s disease symptoms
October 23, 2018 - Knowledge of sex differences in lower urinary tract may help stimulate breakthroughs in diagnosis, management
October 23, 2018 - Common antibodies associated with myocardial infarction
October 23, 2018 - Study reveals new treatment option for women with advanced breast cancer resistant to hormone therapy
October 23, 2018 - Brain’s ‘Self-Control’ Center May Be Key to Weight-Loss Success
October 23, 2018 - Prosthetic valve mismatches common in transcatheter valve replacement, ups risk of death
October 23, 2018 - Can virtual reality help people become more compassionate?
October 23, 2018 - Screen time eclipsed outdoor time for most students, shows study
October 23, 2018 - SLU researcher seeks to find solutions for ‘chemo brain’ symptoms and side effects of opioids
October 23, 2018 - Plastics now commonly found in human stools
October 23, 2018 - Zoledronic acid increases disease-free survival in premenopausal women with HR+ early breast cancer
October 23, 2018 - Cancer survivors at risk for heart failure during, after pregnancy
October 23, 2018 - Stanford project brings health education videos to mothers in South Africa
October 23, 2018 - HIV-infected Hispanics at higher risk of developing HPV-related cancers, finds study
October 23, 2018 - Politicians hop aboard ‘Medicare-for-all’ train, destination unknown
October 23, 2018 - Study suggests rising childhood obesity rates as cause for serious hip disease in adolescents
October 23, 2018 - Study highlights existence of barriers to early clinical trial access for adolescents and young adults
October 23, 2018 - Protein sequencing technique could revolutionize biomedical research
October 23, 2018 - Canon Medical to showcase world’s first Ultra-High Resolution CT system at ASTRO 2018
October 23, 2018 - Spectrum Pharmaceuticals Announces Release of Updated Poziotinib Data From MD Anderson Phase 2 Study in Non-Small Cell Lung Cancer Patients
October 23, 2018 - Cancer stem cells use ‘normal’ genes in abnormal ways
October 23, 2018 - Bad Blood: A conversation with investigative reporter John Carreyrou | News Center
October 23, 2018 - As U.S. fertility rates collapse, finger-pointing and blame follow
October 23, 2018 - Researchers develop promising targeted strategy to treat chemo-resistant blood cancer
October 23, 2018 - Pilot clinical trial shows effectiveness of bioelectronic medicine device for lupus
October 23, 2018 - Genentech’s combination therapy improves outcome in patients with non-squamous non-small cell lung cancer
October 23, 2018 - 11th World Stroke Congress examines high stroke impact in low- and middle-income countries
October 22, 2018 - Breast cancer survival could be extended with two new drug combinations
October 22, 2018 - Researchers discover how acne-causing bacteria resist treatment
October 22, 2018 - Cancer trial shows treating the prostate with radiotherapy improves survival
October 22, 2018 - New hope for a drug to treat lymphedema symptoms
October 22, 2018 - Immune-Based Treatment Helps Fight Aggressive Breast Cancer, Study Finds
October 22, 2018 - Takeda announces positive Phase 3 ALTA-1L data in first-line therapy for advanced ALK+ NSCLC
October 22, 2018 - Paternal exercise has significant impact on child’s lifelong metabolic health
October 22, 2018 - Targeting specific genomic mutation in breast cancer improves survival
October 22, 2018 - Loss of tumor protein p53 helps cancer cells grow in hostile environment
October 22, 2018 - IDT to demonstrate CRISPR expertise at European-focused events
October 22, 2018 - Breathing through the nose improves memory consolidation
October 22, 2018 - Recreational Marijuana Now Legal in Canada
October 22, 2018 - Scientists reveal drumming helps schoolchildren diagnosed with autism
October 22, 2018 - A stage IV cancer patient discusses what it means to live well with serious illness
October 22, 2018 - In Kids with Autism, Short Questionnaire May Detect GI Disorders
October 22, 2018 - Innovative strategy opens up new avenue of treatment for anthrax infections
October 22, 2018 - Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas
October 22, 2018 - Aspirin may be effective in preventing blood clots after knee replacement
October 22, 2018 - Drug cocktail that increases lifespan discovered
October 22, 2018 - Gilead Sciences presents Phase 3 results of filgotinib in biologic-experienced rheumatoid arthritis at 2018 ACR/ARHP Annual Meeting
October 22, 2018 - Study shows potential positive impact of group prenatal care on birth outcomes
October 22, 2018 - Immunotherapy with pembrolizumab extends survival in metastatic or recurrent head and neck cancer
October 22, 2018 - Health Tip: Keep Ticks Away
October 22, 2018 - Obsessive-compulsive disorder – Genetics Home Reference
October 22, 2018 - Researchers find disrupted functional connectivity in cerebellum of adults with HF-ASD
October 22, 2018 - Deciphera presents Phase 1 clinical results of DCC-2618 in patients with gastrointestinal stromal tumors
October 22, 2018 - Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma
October 22, 2018 - Overcoming bottlenecks in early drug discovery with the power of sound
October 22, 2018 - Scientists discover genes that contribute to ADHD development
October 22, 2018 - Incyte announces Phase 2 FIGHT-202 trial data in patients with cholangiocarcinoma
October 22, 2018 - FDA approves update to Rituxan label to include information on treatment of rare forms of vasculitis
October 22, 2018 - At-home biofeedback therapy effective in relieving difficult-to-treat constipation
October 22, 2018 - Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer
October 22, 2018 - People with periodontal disease less likely to reach healthy blood pressure ranges
October 22, 2018 - Phase III LONSURF study shows progression-free survival in patients with refractory metastatic gastric cancer
October 22, 2018 - Primary care doctors ‘not doing enough’ to curb STDs
October 22, 2018 - Pfizer announces PALOMA-3 trial results in patients with HR+, HER2- metastatic breast cancer
October 22, 2018 - ImmunoGen announces study results of platinum-resistant ovarian cancer therapy at ESMO 2018 Congress
October 22, 2018 - Study findings could set new standard of care for advanced anal cancer
October 22, 2018 - Erlotinib improves progression-free survival in EGFR mutated NSCLC
Prenatal test to determine child’s rhesus factor found to be reliable, but benefit is unclear

Prenatal test to determine child’s rhesus factor found to be reliable, but benefit is unclear

image_pdfDownload PDFimage_print

If the blood of a pregnant woman is rhesus-negative (Rh-negative) and the blood of the fetus is rhesus-positive (Rh-positive), the woman may develop antibodies, which can cause severe harm to subsequent children in particular. In order to prevent this effect called sensitization, all Rh-negative pregnant women in Germany currently receive a prophylaxis. A new type of test using a blood sample of the pregnant woman can determine the child’s rhesus factor already before birth, however. Provided the test is sufficiently reliable, many women might not need the prophylaxis. Currently, the blood of the newborn baby is tested directly after birth.

The German Institute for Quality and Efficiency in Health Care (IQWiG) has now examined whether the management of prophylaxis based on this test has advantages or disadvantages for the children or for the expectant mothers. The final results are now available. According to the findings, there are no studies to answer this question. The reliability of the new test is as high as the reliability of the conventional test used after birth, however.

Risk particularly in subsequent pregnancies

The rhesus factor is an inherited characteristic of the red blood cells (erythrocytes). It acts as an antigen, i.e. Rh-negative people can produce antibodies against foreign Rh-positive blood cells in their blood. This can cause severe, even fatal incompatibility reactions. The rhesus factor therefore plays an important role in blood transfusion and pregnancy.

During pregnancy, and particularly during birth, the blood of an Rh-positive child can enter the bloodstream of the Rh-negative mother. This causes the production of antibodies in a process called sensitization. These antibodies can enter the child’s bloodstream, causing anemia, cardiac failure, brain damage, or even death of the fetus.

However, not the fetus of the current pregnancy, but Rh-positive children in subsequent pregnancies are the ones who carry the greatest risk. The reason is that these children are subject to the defense reaction of their mother’s blood at a very early stage of the pregnancy.

Standard prophylaxis for all rhesus-negative pregnant women

All Rh-negative pregnant women in Germany currently receive a standard dose of anti-D immunoglobulin. These antibodies are used to prevent sensitization by catching erythrocytes that reach the mother’s bloodstream from the fetal bloodstream already before birth. Human anti-D immunoglobulin from sensitized donors is used for this prophylaxis.

After birth, the infant’s rhesus factor is determined using a blood sample of the infant (postnatal testing). If the blood of the newborn is Rh-positive, the mother receives another anti-D prophylaxis.

Mother’s blood contains information on the fetal rhesus factor

Now a test has become available to determine the fetal rhesus factor already before birth. This is a non-invasive procedure, in which the fetus is not touched. Instead, the test analyses so-called cell-free fetal DNA circulating in the maternal plasma.

In principle, this allows limiting prenatal anti-D prophylaxis only to those Rh-negative pregnant women whose fetus is Rh-positive according to the prenatal test. Currently, about 15 per cent of all pregnant women receive the prophylaxis, corresponding to about 110 000 pregnant women per year. Implementing the new test could reduce this number to about 60 000.

Studies cannot answer the research question of the commission

The Federal Joint Committee (G-BA), which is also responsible for the German “maternity guidelines”, therefore wanted to know from IQWiG whether the introduction of the new test can have health advantages or disadvantages for children or mothers, e.g. increasing the occurrence of hemolytic anemia or decreasing the occurrence of side effects of the prophylaxis.

The IQWiG researchers found out that there are currently no studies that allow drawing precise conclusions on the effects the introduction of the new test might have.

Both tests equally reliable

However, there are studies that provide information on how reliable the prenatal test is in determining the child’s rhesus factor. The reliability is comparatively high, which is referred to as “high diagnostic accuracy”: The test correctly identifies 99.9 per cent of all Rh-positive fetuses (sensitivity) and 99.1 per cent of all Rh-negative fetuses (specificity). This means that 0.1 per cent of pregnant women who would require anti-D prophylaxis before birth would not receive this prophylaxis if this decision was based on the test result. Hence, the prenatal test is as reliable as testing after birth.

Balancing possible advantages and disadvantages

The new test allows using the anti-D prophylaxis when it is needed and spare some pregnant women from unnecessary prenatal prophylaxis. It is unclear whether these pregnant women have an advantage, however, because reliable data on possible side effects of the prophylaxis are missing.

The risk that false test results might lead to additional sensitizations is considered low, despite the lack of sufficient data. On the one hand, the test can be rated as very reliable. On the other, the risk is low that sensitization occurs already during pregnancy.

In its report, the Institute did not address the question which effects it might have at the level of the German health care system if a large number of unnecessary anti-D prophylaxis are avoided. General aspects of importance are not only the financing of this prophylaxis, but also its acquisition and ethical aspects, however, because male donors are sensitized with a blood product to produce the vaccine. The number of donors worldwide is limited, and Germany has to import the preparations.

Prenatal test suitable to replace postnatal test

If the prenatal test was to replace the postnatal test, this would increase neither the rate of prophylaxis that is falsely withheld nor the rate of hemolytic anemia to a measurable extent. This is because both tests are equivalent. It is recommended, however, to evaluate the procedure first and particularly to test how high the sensitivity of the new prenatal test actually is under the health care conditions in Germany. Only after this evaluation, a safe decision could be made whether postnatal testing is in fact dispensable. Responsible authorities in Denmark and the Netherlands, where only prenatal testing is used nowadays, also had arranged for prior evaluation.

Process of report production

IQWiG published the preliminary results in the form of the preliminary report in October 2017 and interested parties were invited to submit comments.At the end of the commenting procedure, the preliminary report was revised and sent as a final report to the commissioning agency in March 2018.The written comments submitted are published in a separate document at the same time as the final report.The report was produced in collaboration with external experts.

Source:

https://www.iqwig.de/en/press/press-releases/prenatal-testing-of-the-foetal-rhesus-factor-test-is-reliable-but-benefit-is-unclear.8983.html

Tagged with:

About author

Related Articles